Urology
Volume 70, Issue 1 , Pages 19-24 , July 2007

Urologists’ Attitudes Regarding Cancer Clinical Research

  • Gregory P. Swanson

      Affiliations

    • University of Texas Health Science Center San Antonio, San Antonio, Texas
    • Southwest Oncology Group Genitourinary Committee, Ann Arbor, Michigan
    • Corresponding Author InformationReprint requests: Gregory P. Swanson, M.D., Departments of Radiation Oncology and Urology, University of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, MC 7889, San Antonio, TX 78229.
    • ,
  • William R. Carpenter

      Affiliations

    • University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
    • ,
  • Ian M. Thompson

      Affiliations

    • University of Texas Health Science Center San Antonio, San Antonio, Texas
    • Southwest Oncology Group Genitourinary Committee, Ann Arbor, Michigan
    • ,
  • E. David Crawford

      Affiliations

    • Southwest Oncology Group Genitourinary Committee, Ann Arbor, Michigan
    • University of Colorado at Denver Health Sciences Center, Denver, Colorado

Received 28 October 2006 ,Accepted 7 March 2007.

References 

  1. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002;20:2109–2117
  2. National Surgical Adjuvant Breast and Bowel Project: NSABP Protocol Chart.. Pittsburgh: National Surgical Adjuvant Breast and Bowel Project; 2006;
  3. Nathan DG. National Institutes of Health Director’s Panel on Clinical Research: Clinical research: perceptions, reality, and proposed solutions. JAMA. 1998;280:1427–1431
  4. U.S. General Accounting Office: NIH Clinical Trials: Various Factors Affect Patient Participation.. Washington, DC: U.S. General Accounting Office; 1999;
  5. Gotay CC. Accrual to cancer clinical trials: directions from the research literature. Soc Sci Med. 1991;33:569–577
  6. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291:2720–2726
  7. Ashar BH, Miller RG, Getz KJ, et al. Prevalence and determinants of physician participation in conducting pharmaceutical-sponsored clinical trials and lectures. J Gen Intern Med. 2004;19:1140–1145
  8. Taylor KM, Feldstein ML, Skeel RT, et al. Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators. J Clin Oncol. 1994;12:1796–1805
  9. Lloyd T, Phillips BR, Aber RC. Factors that influence doctors’ participation in clinical research. Med Educ. 2004;38:848–851
  10. Weinberg AD, Cooper HP, Mejia NI, et al. Attitudes of primary care physicians and specialists about cancer clinical trials: a survey of Texas physicians. Tex Med. 2004;100:66–72
  11. Carpenter W, Weiner B, Kaluzny A, et al. The effects of managed care and competition on community-based clinical research. Med Care. 2006;44:671–679
  12. Norman G, Streiner D. Biostatistics: The Bare Essentials. Baltimore: Mosby; 1994;
  13. Stata/SE Statistical Software [computer program], version 9.1. College Station, Texas, Stata Press, 2005.
  14. O’Leary MP, Baum NH, Bohnert WW, et al. 2003 American Urological Association Gallup survey: physician practice patterns, cryosurgery/brachytherapy, male infertility, female urology and insurance/professional liability. J Urol. 2004;171(Pt 1):2363–2365
  15. Smalley RV, Murphy S, Huguley CM, et al. Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res. 1976;36:3911–3916
  16. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930–942
  17. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124–1129
  18. Okeke AA, Probert JL, Gillatt DA, et al. Is intravesical chemotherapy for superficial bladder cancer still justified?. BJU Int. 2005;96:763–767
  19. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–1659
  20. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520

 This study was funded by the Southwest Oncology Group (National Cancer Institute grant CA 32102) for general clinical research and the HOPE Foundation for direct support of the survey (printing, mailing, compiling data). E. D. Carpenter was supported by a training grant from the National Cancer Institute (grant R25T CA 57726).

PII: S0090-4295(07)00370-6

doi: 10.1016/j.urology.2007.03.019

Urology
Volume 70, Issue 1 , Pages 19-24 , July 2007

Article Tools